Michelle Krogsgaard

Michelle Krogsgaard is an Associate Professor in the Department of Pathology at NYU Grossman School of Medicine, where she leads the Krogsgaard Lab at the Smilow Research Center in New York. Her research focuses on the molecular mechanisms of T-cell receptor (TCR) signaling in the context of cancer immunology, autoimmunity, and immunotherapy development.

Research Interests: Dr. Krogsgaard's work lies at the intersection of immunology, biophysics, and structural biology. Her lab investigates how T cells recognize antigens, with a particular emphasis on TCR sensitivity, receptor signaling dynamics, and the structural basis of immune recognition. This includes studying neoantigens, TCR-CD3 complex assembly, and strategies to enhance immunotherapy while minimizing autoimmune side effects.

Publication Trends: Her recent publications, appearing in high-impact journals such as Nature, Cell Reports, and PNAS, reflect a strong trajectory in structural immunology and translational cancer research. Themes include TCR engineering, phosphopeptide immunogenicity, mitochondrial influences on immune response, and the balance between antitumor efficacy and autoimmunity. The work combines molecular, structural, and clinical approaches to advance precision immunotherapy.

Scientific Awards:

• No specific awards are listed in the provided text.

Advising and Grants: Dr. Krogsgaard leads an active research laboratory and mentors trainees in immunology and cancer research. Her lab has received support from programs such as the Blood Cancer Pilot Grants, which fund translational research in novel immunotherapies. While specific grant amounts and student names are not provided, her extensive publication record and lab leadership indicate a robust program of funded research and academic mentorship.

Labs and Teams: The Krogsgaard Lab is based at the Smilow Research Center and employs a multidisciplinary approach, including structural biology, animal models, and human tissue analysis. The team investigates fundamental TCR signaling mechanisms to inform the development of safer and more effective cancer immunotherapies.